Table 4.
PFH of diseases in first- or second-degree relatives of CBP patients meeting the ASAS axSpA criteria, stratified according to HLA-B27 status
| Positive family history | SPACE cohort n = 201* | DESIR cohort n = 409** | ||
|---|---|---|---|---|
| HLA-B27+ | HLA-B27– | HLA-B27+ | HLA-B27– | |
| Any PFH | 90 (45%) | 14 (7%) | 145 (35%) | 24 (6%) |
| AS | 59 (29%) | 2 (1%) | 92 (23%) | 5 (1%) |
| AAU | 22 (11%) | 1 (1%) | 26 (6%) | 0 (0) |
| ReA | 4 (1%) | 1 (1%) | 1 (0.2%) | 1 (0.2%) |
| IBD | 11 (6%) | 5 (3%) | 14 (3%) | 5 (1%) |
| Psoriasis | 32 (16%) | 9 (5%) | 65 (16%) | 20 (5%) |
*Two hundred and three patients fulfilled ASAS-criteria, two with unknown HLA-B27 status
**Four hundred and ten patients fulfilled ASAS-criteria, one with unknown HLA-B27 status
AAU acute anterior uveitis, AS ankylosing spondylitis, ASAS axSpA Assessment of Spondyloarthritis international Society criteria for axial spondyloarthritis, HLA-B27 human leucocyte antigen B27, IBD inflammatory bowel disease, PFH postitive family history (manifestation in first- or second-degree relatives), ReA reactive arthritis